ELEKTA AB/ADR (OTCMKTS:EKTAY) Downgraded by Zacks Investment Research to “Hold”

Zacks Investment Research downgraded shares of ELEKTA AB/ADR (OTCMKTS:EKTAY) from a buy rating to a hold rating in a report issued on Monday morning, Zacks.com reports.

According to Zacks, “Elekta AB is a human care company engaged in developing and selling clinical solutions for the treatment of cancer and neurological diseases. It develops tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. The Company’s offering is divided into five areas: Neuroscience, Oncology, Software, Brachytherapy and Services. Elekta AB is headquartered in Stockholm, Sweden. “

Separately, ValuEngine cut shares of ELEKTA AB/ADR from a hold rating to a sell rating in a research report on Thursday, November 14th.

Shares of EKTAY traded down $0.54 during mid-day trading on Monday, hitting $12.57. The company’s stock had a trading volume of 4,781 shares, compared to its average volume of 4,339. The company’s 50-day moving average is $13.31 and its 200-day moving average is $13.18. ELEKTA AB/ADR has a 52-week low of $10.95 and a 52-week high of $14.76. The firm has a market capitalization of $5.01 billion, a price-to-earnings ratio of 38.08, a PEG ratio of 2.60 and a beta of 0.46. The company has a current ratio of 1.08, a quick ratio of 0.86 and a debt-to-equity ratio of 0.46.


Elekta AB (publ) provides equipment and software for cancer and brain disorders worldwide. The company offers radiotherapy systems under the Versa HD, Precise Treatment System, and Elekta Compact names; Elekta Infinity, an image-guided radiation therapy (IGRT) system; and Elekta Synergy, a digital accelerator for advanced IGRT.

See Also: Arbitrage

Get a free copy of the Zacks research report on ELEKTA AB/ADR (EKTAY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ELEKTA AB/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ELEKTA AB/ADR and related companies with MarketBeat.com's FREE daily email newsletter.